|
||||||||||||||||||||||||||||||
|
|
| Upcoming Programs | ||||||
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||
Overview
TBD
Objectives
Faculty
Overview
More than 20 million people in the United States are affected by diabetes, with 1.5 million new cases appearing each year. Of this population, nearly 65% will die from heart disease or stroke, a rate that is 4-times higher than in the non-diabetic population. Individualized and early glycemic control is critical in the prevention and management of diabetes and in reducing cardiovascular risk. This activity will expose attendees to the relationship between insulin resistance, type 2 diabetes, and the resulting cardiovascular risk in an effort to uncover effective treatment strategies and patient-based therapeutic options.
Objectives
Utilize appropriate glucose-lowering agents to reduce A1C to * 7.0%
Minimize adverse events and cardiovascular risk associated with glycemic therapy by employing appropriate glucose, blood pressure, and serum cholesterol agents
Faculty
Anne Peters, MD
Thomas A. Buchanan, MD
Professor
Chief, Division of Endocrinology
Keck School of Medicine
University of Southern California
Los Angeles, CA
Overview
Bipolar disorder (BD) and major depressive disorder (MDD) are two of the most prevalent psychiatric disorders in adults. These conditions are associated with overlapping disorders of mood including anxiety and depression; differentiating the two disorders can be difficult and can lead to misdiagnosis and mismanagement. This activity will focus on practical approaches to the diagnosis and management of the Òdifficult-to-treatÓ patient presenting with depression associated with MDD and BD.
Objectives
Recognize overlapping symptomatology and comorbid psychiatric disorders that can complicate the differential diagnosis of depression
Design and implement practical strategies to diagnosis and manage the difficult-to-treat patient with depression associated with major depressive disorder and bipolar disorder
Faculty
Larry Culpepper, MD, MPH
Professor of Family Medicine
Department of Family Medicine Chair
Boston University School of Medicine
Chief of Family Practice
Boston Medical Center
Boston, MA
Overview
Healthcare providers and patients alike receive confusing, and even seemingly conflicting, data about the benefit-risk ratio associated with menopausal hormone therapy (HT). In this program, the faculty will present risk concepts in general as well as the most current evidence regarding HT risks and benefitsÑ and how to clearly explain this evidence to their diverse patient population for which HT is considered. The goal of the program is to avoid misperception about HT riskÑand, therefore, faulty decision making.
Objectives
Define absolute risk, relative risk, and clinically significant risk of adverse events and exposure history in meaningful terms as it relates to hormone therapy
Identify clinical guidelines and evidence-based approaches for counseling a diverse patient population on the potential benefits and risks of hormone therapy
Faculty
Bruce Ettinger, MD
Emeritus Clinical Professor Medicine
University of California, San Francisco
San Francisco, CA
Adjunct Investigator
Division of Research
Kaiser Permanente Medical Care Program
Oakland, CA
Cynthia A. Stuenkel, MD
Clinical Professor of Medicine
University of California, San Diego
La Jolla, CA
Overview
An estimated 1 million cases of herpes zoster (shingles) occur annually in the United States. The incidence and severity of herpes zoster increase with advancing age to produce substantial negative effects on quality of life, activities of daily living, neuropsychological functioning, and social status, resulting in significant morbidity in older adults. While antiviral therapy reduces the incidence and severity of herpes zoster, it does not reliably prevent postherpetic neuralgia (PHN), the most common and debilitating clinical sequela of herpes zoster. Herpes zoster vaccination has been demonstrated to reduce the incidence of the disease and its complications. Clinical trial data have demonstrated significant reductions in the incidence of herpes zoster and PHN, as well as overall reductions in the burden of disease.
Objectives
Review the benefits and limitations of current treatment options for herpes zoster and postherpetic neuralgia (PHN)
Evaluate clinical trial results of the herpes zoster vaccine and discuss current recommendations of the Advisory Committee on Immunization Practices for the prevention of herpes zoster
Faculty
John F. Trowbridge, MD, CPE
Director, Chronic Conditions Management
Kaiser Permanente Santa Rosa
Clinical Professor of Medicine
University of California at San Francisco
San Francisco, CA
Lawrence D. Gelb, MD
Professor of Medicine, Department of Internal Medicine
Division of Infectious Diseases
Washington University School of Medicine
St. Louis, MO
Overview
Human papillomavirus (HPV) is the most common newly acquired sexually transmitted infection in the United States. It is a necessary cause of cervical cancer and genital warts, and is associated with other anogenital and head and neck cancers, and recurrent respiratory papillomatosis. Prevention of HPV infection through prophylactic vaccination provides a safe and effective option to reduce the health burden associated with HPV-related diseases. Two vaccines have been developed: a quadrivalent HPV (6, 11, 16, 18) vaccine, approved by the US Food and Drug Administration (FDA), and a bivalent HPV (16, 18) vaccine, currently under FDA review. Both vaccines have demonstrated lasting efficacy against HPV-associated cervical disease and are generally well tolerated. This program will review the health consequences of HPV infection; provide an update on the safety and efficacy of HPV vaccines, including recent data on efficacy in mid-adult women, duration of protection, and cross-protection against nonvaccine HPV types; and evaluate the benefits of widespread HPV vaccination in preventing HPV-related diseases.
Objectives
Describe the epidemiology, natural history and consequences of HPV infection
Evaluate the anticipated benefits of widespread HPV vaccination in preventing cervical and anogenital cancers, genital warts, and other HPV-related diseases
Faculty
J. Thomas Cox, MD
Director, The Women's Health Clinic
Student Health Services
University of California, Santa Barbara
Santa Barbara, CA
Daron G. Ferris, MD
Professor
Department of Family Medicine
Department of Obstetrics and Gynecology
Director, Gynecologic Cancer Prevention Center
Medical College of Georgia
Augusta, GA
Overview
Optimal Use of Analgesics in the Management of Osteoarthritis Pain will provide an evidence-based, guideline-based review of treatment options for managing osteoarthritis pain. Video-vignette, case-based learning will be used to illustrate education from expert presentations and guidelines. Special emphasis will be placed on physician-patient communication regarding pain management.
Objectives
Implement strategies for patient communication and education for management of OA pain and utilize pharmacologic and nonpharmacologic therapies for pain management according to guideline recommendations
Describe patient risk factors which could interact with various pain relief medications
Faculty
Frank LoVecchio, DO, MPH
Professor
Arizona College of Osteopathic Medicine
Midwestern University
Glendale, Arizona
Michael J. Cawley, PharmD
Associate Professor of Clinical Pharmacy
Philadelphia College of Pharmacy
Philadelphia, Pennsylvania
Overview
ÒMore Than Skin Deep: Clinical Strategies for Acne Vulgaris and Actinic KeratosisÓ is a continuing medical education program that aims to bridge some of the existing professional practice gaps that primary care clinicians may have regarding common dermatologic problems. This program will educate clinicians in the primary care setting about the prevalence, impact, diagnosis, and treatment of both acne vulgaris and actinic keratosis.
Objectives
Confidently diagnose patients presenting with the basic dermatologic conditions of acne vulgaris and actinic keratosis
Identify the most commonly used treatments for acne vulgaris and actinic keratosis
Faculty
Brian Berman, MD
Guy Webster, PhD
Overview
The term acute coronary syndrome (ACS) is used to describe patients who present with either acute MI or unstable angina (UA). This program will provide an overview of ACS by discussing epidemiology, prevalance, acute and long term care treatment options as well as review current guidelines. Implementation of current treatment guidelines and patient adherence strategies in the primary care setting will also be discussed.
Objectives
Name 5 treatment recommendations for reduction of global CV risk in patients being medically managed for UA/NSTEMI
Describe 2 situations where dual antiplatelet therapy is recommended in patients with acute coronary syndrome
Faculty
Philip Altus, MD, MACP
Professor of Medicine Emeritus
University of South Florida
Tampa, FL
Martin W. Schwarze, DO, FACC
Clinical Professor of Medicine
St. Louis University School of Medicine
St. Louis, MO
Overview
Allergic rhinitis (AR) is the most common allergic condition in the US, affecting nearly 40 million people. Although AR is associated with significant comorbidities, current therapies have proven only modestly successful. Allergic Rhinitis and Its Comorbidities: A Serious Challenge to the Health Care Professional will provide primary care physicians with practical, evidence-based solutions to the challenges of managing AR, with particular emphasis on finding effective treatments and ensuring patient compliance. Two nationally recognized allergy/immunology experts will lead each 75-minute presentation with 60 minutes of didactic lectures and case history presentation, and a 15-minute question-and-answer session. Interactive discussion and a dynamic audience response system will also be integrated into the session.
Objectives
Describe key clinical characteristics of allergic rhinitis, its associated comorbidities, and its impact on patient health and quality of life
Identify barriers to treatment success of allergic rhinitis (treatment-related, physician-related, and patient-related barriers) and adequate control of symptoms, and devise strategies for overcoming those barriers
Faculty
Bradley E. Chipps, MD
Medical Director, Cystic Fibrosis Center and Respiratory Therapy
Capital Allergy and Respiratory Disease Center
Associate Medical Director, Sleep Laboratory
Sutter Medical Center
Sacramento, CA
Eli Meltzer, MD
Clinical Professor of Pediatrics
University of California, San Diego, School of Medicine
Co-Director
Allergy and Asthma Medical Group and Research Center
San Diego, California
Overview
This program is designed to provide primary care providers with information about the state of the science and evidence-based strategies for the accurate identification and comprehensive treatment of osteoporosis.
Objectives
Identify appropriate diagnostic tools & procedures that can be employed for early diagnosis of osteoporosis
Evaluate the treatment strategies, including methods of administration and MOAs of various antiresorptive agents that are currently available to prevent fractures and treat osteoporosis
Faculty
Richard Pittsley, MD